scholarly journals Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Simona Delia Nicoară ◽  
Constanța Nascutzy ◽  
Cristina Cristian ◽  
Iulian Irimescu ◽  
Anne Claudia Ștefănuț ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Retinopathy Of Prematurity ◽  
Case Series ◽  
Intravitreal Bevacizumab ◽  
Retrospective Case ◽  
Intravitreal Bevacizumab Injection ◽  
Postmenstrual Age ◽  
Registration Number ◽  
Bevacizumab Injection

Purpose. This study aims to evaluate the regression of retinopathy of prematurity (ROP) after one intravitreal injection of bevacizumab and the factors that influenced it.Methods. This retrospective case series was carried out at the “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania. It includes all the consecutive infants treated for ROP with one intravitreal bevacizumab injection, from January 1, 2009, throughout July 31, 2013. The follow-up continued for 60 weeks after injection. We recorded ROP classification, regression, gender, gestational age, birth weight, postnatal age and postmenstrual age at treatment, and pregnancy type. Regression was analyzed according to each of the abovementioned factors, with the program IBM SPSS 20 (Chicago, Illinois, USA).Results. This study includes 74 eyes of 37 infants of which 52 had aggressive posterior ROP (70.27%) and 22 had zone I stage 3+ ROP (29.72%). One week after the bevacizumab injection, ROP regressed in 63 eyes (85.13%), with a statistically significant higher rate in zone I stage 3+ ROP (100%), as compared with aggressive posterior ROP (78.84%) (P=0.03). We recorded no complications subsequent to the intravitreal injections of bevacizumab. We identified no late retinal detachment.Conclusion. ROP regression rate after one intravitreal bevacizumab injection was 85.13%. This trial is registered with trial registration numberIRCT2014101618966N2.

scholarly journals Posterior Pole Sparing Laser Photocoagulation Combined with Intravitreal Bevacizumab Injection in Posterior Retinopathy of Prematurity

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Rebecca Kim ◽  
Yu Cheol Kim
Keyword(s):  
Laser Ablation ◽  
Retinopathy Of Prematurity ◽  
Laser Photocoagulation ◽  
Intravitreal Bevacizumab ◽  
Retrospective Chart Review ◽  
Posterior Pole ◽  
Intravitreal Bevacizumab Injection ◽  
Premature Babies ◽  
Postmenstrual Age ◽  
Bevacizumab Injection

Purpose. To report the results of the posterior pole sparing laser photocoagulation combined with intravitreal bevacizumab injection (IVB) in retinopathy of prematurity (ROP).Methods. A retrospective chart review of premature babies with ROP, all of whom received laser photocoagulation with IVB. Eleven eyes of 6 infants with advanced zone I ROP underwent laser ablation sparing posterior pole with concurrent IVB. The results were compared with those of full-laser treatment combined with IVB to 8 eyes of 5 infants with advanced ROP without involvement of the posterior pole.Results. The posterior pole sparing laser with IVB was performed with zone I, stage 3+ ROP at the mean postmenstrual age of 36 weeks and 5 days. The plus sign decreased significantly at postoperative day 1, the neovascular proliferation regressed by postoperative week 1, and the normal vascularization started at postoperative day 32 on the average. Two months after treatment, vascularization of the spared avascular area was completed. There was no macular dragging, tractional retinal detachment, foveal destruction by laser scars, or any other adverse event. No significant anatomical differences were identified from those of full-laser ablation combined with IVB.Conclusions. Posterior pole sparing laser with IVB can give favorable results without destruction of posterior pole retina.

Conserved regression patterns of retinopathy of prematurity after intravitreal ranibizumab: A class effect

2020 ◽  
pp. 112067212094510
Author(s):  
Marco H Ji ◽  
Darius M Moshfeghi ◽  
Ryan A Shields ◽  
Zachary Bodnar ◽  
Cassie A Ludwig ◽  
...  
Keyword(s):  
Retinopathy Of Prematurity ◽  
Case Series ◽  
Intravitreal Bevacizumab ◽  
Class Effect ◽  
Intravitreal Ranibizumab ◽  
Retrospective Case ◽  
Avascular Area ◽  
Peripheral Ischemia ◽  
Stage Disease ◽  
Postmenstrual Age

Purpose: To determine if fluorescein angiographic (FA) findings after intravitreal ranibizumab (IVR) for retinopathy of prematurity (ROP) conform to a class effect previously described with bevacizumab. Methods: Single-center retrospective case series of all infants treated with 0.2 mg (0.02 mL) IVR for Type 1 ROP from July 2016 to November 2018. FA were obtained at 40, 52, 62, and 72 weeks of postmenstrual age (PMA) using wide-angle photography. FA images were analyzed and the peripheral avascular areas measured with ImageJ using a reference disc diameter (DD). Based on the extent of the avascular area and tortuosity of the retinal vessels all eyes were classified into four categories: complete vascular maturity (vascularization within 2 DD of the ora serrata), VAA (avascular area >2 DD of the ora serrata), VAT (avascular area >2 DD of the ora serrata and posterior tortuosity), and reactivation (recurrence of stage disease). Results: About 13 infants were enrolled and 24 eyes were available in this study. None of the eyes reached complete vascular maturity at an average PMA of 60 weeks, 7 (29%) eyes presented with VAA, 8 (33%) with VAT, and 9 (37.5%) reactivated. The reactivated eyes presented with the largest area of peripheral ischemia, followed by the VAT and then the VAA groups ( p = 0.02). Conclusion: IVR conforms to the previously described regression patterns following intravitreal bevacizumab for ROP indicative of a class effect. Follow-up using FA might help to optimize the management of these infants after injection of the drug.

Sign in / Sign up

Export Citation Format

Share Document